3 Reasons It's Not Too Late to Buy Moderna Stock
Some investors think the ship has already sailed when it comes to investing in Moderna (NASDAQ: MRNA). With a market cap of well over $50 billion, Moderna's opportunities for its COVID-19 vaccine mRNA-1273 seem to largely be baked into its share price.
I'd definitely agree that Moderna's valuation a couple of months ago was much more attractive than it is now. However, I don't think it's necessarily too late to buy the biotech stock. Here are three reasons why.
Image source: Getty Images
Source Fool.com
